)
Rhythm Pharmaceuticals (RYTM) investor relations material
Rhythm Pharmaceuticals Stifel 2026 Healthcare Conference 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.U.S. AHO launch
More than 700 start forms and ~500 unique HCP prescribers reported after approval in March; 25% of HCPs were repeat prescribers.
Excluding clinical trial patients, the Q2 pace continued through October; management expects the pace to continue, supported by broad reach across targeted endocrinologists.
Endocrinology capacity and patients’ regularly scheduled visits for hormone replacement can limit how quickly diagnosed patients move to treatment.
Payer adoption of positive coverage policies has been faster than for BBS, supported by existing drug availability, stronger data and the severity of the underlying injury.
Through 2027, priorities include broadening patients on therapy, increasing HCP reach and repeat prescribing, and supporting continued revenue growth.
Japan and other ex-U.S. markets
AHO was approved in Japan in October; more than 1,000 patients have been identified and treatment has begun.
First-year Japanese uptake is expected to be modest because prescriptions must be renewed every two weeks for the first 12 months; management expects launch momentum to build after the restriction lifts.
Japan AHO prevalence is estimated at 5,000–8,000 patients, versus ~10,000 in the U.S.; management cited higher craniopharyngioma incidence, expected higher diagnosis and supportive market conditions.
Germany reimbursement exception is expected in Q1, followed by launch; France launch is anticipated in 2027 after supplemental price negotiation, while Italy and U.K. access efforts are also progressing.
Management expects a higher ex-U.S. AHO contribution in 2027 as launches take hold, with more specific timelines to come early in the year.
Bivamelagon and Prader-Willi syndrome
A licensing amendment commits $350 million over four years to reduce bivamelagon royalties from 5%–7% to 1%, removing an economic disincentive to development.
Bivamelagon is planned to lead next-generation PWS development; management hopes to meet the FDA in 2027 and start a hyperphagia-focused study that year.
The proposed PWS Phase III study is six months, placebo-controlled, with HQ-CT as the primary endpoint; clinically meaningful hyperphagia measured by HQ-CT is expected to be an entry criterion.
In Phase II, all six adults with clinically meaningful hyperphagia had HQ-CT reductions through six months, as did three of five children; management expects placebo effects to normalize by six months.
Bivamelagon was selected ahead of RM-718 based on clinical supply readiness, KOL feedback favoring daily routine administration, and the revised royalty economics.
- Steady HO launch progress and expanding MC4R trials support a growing opportunity.RYTM
3rd Annual Guggenheim Healthcare Innovation Conference - IMCIVREE sales rose 29% as Japan launched and bivamelagon advanced toward Phase 3.RYTM
Q3 2026 - Early HO launch shows strong physician interest and payer adoption, with global expansion planned.RYTM
Morgan Stanley 24th Annual Global Healthcare Conference - HO launch gains traction, Prader-Willi trials advance, and financials support robust investment.RYTM
Wells Fargo 21st Annual Healthcare Conference - IMCIVREE drives global growth as MC4R therapies expand for rare obesity syndromes.RYTM
Corporate presentation - Strong AHO launch, global expansion, and advancing pipeline position the company for growth.RYTM
Canaccord Genuity's 46th Annual Growth Conference - Q2 2026 revenue climbed 47% to $71.3M, led by IMCIVREE's U.S. launch and global expansion.RYTM
Q2 2026 - Q3 2025 revenue up 54% to $51.3M, net loss $54.3M, $416.1M cash, key milestones ahead.RYTM
Q3 2025 - IMCIVREE sales and pivotal trial success drive revenue growth and improved financial outlook.RYTM
Q1 2025
)
)
)
)
)
)
)
)